瑞舒伐他汀联合环磷腺苷葡胺治疗急性心肌梗死对患者血清血管内皮生长因子-B和生长分化因子15水平的影响

目的探讨瑞舒伐他汀联合环磷腺苷葡胺治疗急性心肌梗死对患者血清血管内皮生长因子-B(VEFG-B)和生长分化因子15(GDF-15)水平的影响。方法选取2018年1月至2019年7月沈阳医学院附属中心医院收治的93例急性心肌梗死患者为研究对象,按照用药方案不同分为两组,对照组予以环磷腺苷葡胺注射液治疗,观察组在对照组基础上采用瑞舒伐他汀钙片治疗。比较两组患者治疗前后血清指标、心功能指标。结果两组患者治疗前各项血清指标比较差异无统计学意义(P>0.05);治疗后,两组肌酸激酶同工酶(CK-MB)、C反应蛋白(CRP)、肌红蛋白(Mb)、GDF-15、N-末端脑钠肽前体(NT-proBNP)、髓过氧化物酶(MPO)、肌钙蛋白Ⅰ(cTnⅠ)、同型半胱氨酸(Hcy)较治疗前明显下降,VEFG-B明显升高,且观察组改善幅度优于对照组,差异有统计学意义(P<0.05)。两组患者治疗前心功能指标比较差异无统计学意义(P>0.05);治疗后,两组每搏量、心输出量、左室射血分数较治疗前明显升高,且观察组高于对照组,差异有统计学意义(P<0.05)。结论采用瑞舒伐他汀联合环磷腺苷葡胺治疗急性心肌梗死,能改善患者心功能,对患者预后具有重要意义。

Effect of Rosuvastatin Combined with Adenosine Cyclophosphamide on Serum VEGF-B and GDF-15 levels in Acute Myocardial Infarction

Objective To explore the effect of rosuvastatin combined with adenosine cyclophosphamide on serum VEGF-B and GDF-15 levels in patients with acute myocardial infarction.Methods A total of 93 patients with acute myocardial infarction admitted to Affiliated Central Hospital of Shenyang Medical College from January 2018 to July 2019 were selected as the research objects,and were divided into 2 groups according to different medication scheme.The control group was treated with meglumine cyclic adenosine injection,and the observation group was treated with rosuvastatin calcium tablets plus meglumine cyclic adenosine injection.The serum indexes and cardiac function indexes of the 2 groups of patients before and after treatment were compared.Results There was no significant difference in serum indexes between the 2 groups before treatment(P>0.05).After the treatment,Ck-MB,CRP,Mb,GDF-15,NT-probNP,MPO,cTnI,Hcy in both groups were significantly decreased compared with those before treatment.Vefg-b was significantly elevated,and the observation group significantly improved more than the control group,the difference was statistically significant(P<0.05).There was no significant difference in cardiac function between the 2 groups before treatment(P>0.05).After treatment,stroke volume,cardiac output and left ventricular ejection fraction in both groups were significantly higher than before treatment,the observation group improved significantly more than the control group,the difference was statistically significant(P<0.05).Conclusion Acute myocardial infarction was treated with rosuvastatin combined with adenosine cyclophosphamide,which can improve the heart function of patients and is of great significance to the prognosis of patients.